Comparison of clinical features of patients treated with HDM/SCT and evaluated at 1 year (n = 181) by availability of SF-36 data at the 1-year follow-up
Feature . | SF-36 completed; n = 104 . | SF-36 unavailable; n = 77 . | P . |
|---|---|---|---|
| Age, y, mean | 56.2 ± 9.8 | 56.6 ± 9.5 | .814 |
| Mo from first symptom to diagnosis* | 6.2 (3.1, 12.4) | 6.0 (2.7, 13.5) | .817 |
| Mo from diagnosis to referral* | 2.8 (1.5, 4.9) | 2.7 (1.5, 4.4) | .678 |
| Performance status at baseline* | 1 (0, 1) | 1 (0, 1) | .363 |
| Performance status at 1 y* | 1 (0, 1) | 1 (0, 1) | .810 |
| No. of organ systems involved at baseline* | 2 (1, 3) | 2 (2, 3) | .804 |
| Organ involvement, % | |||
| Heart | 34.6 | 28.6 | .389 |
| Kidney | 89.4 | 84.4 | .317 |
| Gastrointestinal/liver | 48.1 | 52.0 | .607 |
| Neuropathy | 42.3 | 48.1 | .442 |
| Soft tissue | 15.4 | 13.0 | .649 |
| Higher melphalan dose received | 64.4 | 59.7 | .520 |
| No. of systems with improvement at 1 y* | 1 (0, 1) | 0 (0, 1) | .021 |
| CR at 1, % | 39.4 | 41.6 | .772 |
Feature . | SF-36 completed; n = 104 . | SF-36 unavailable; n = 77 . | P . |
|---|---|---|---|
| Age, y, mean | 56.2 ± 9.8 | 56.6 ± 9.5 | .814 |
| Mo from first symptom to diagnosis* | 6.2 (3.1, 12.4) | 6.0 (2.7, 13.5) | .817 |
| Mo from diagnosis to referral* | 2.8 (1.5, 4.9) | 2.7 (1.5, 4.4) | .678 |
| Performance status at baseline* | 1 (0, 1) | 1 (0, 1) | .363 |
| Performance status at 1 y* | 1 (0, 1) | 1 (0, 1) | .810 |
| No. of organ systems involved at baseline* | 2 (1, 3) | 2 (2, 3) | .804 |
| Organ involvement, % | |||
| Heart | 34.6 | 28.6 | .389 |
| Kidney | 89.4 | 84.4 | .317 |
| Gastrointestinal/liver | 48.1 | 52.0 | .607 |
| Neuropathy | 42.3 | 48.1 | .442 |
| Soft tissue | 15.4 | 13.0 | .649 |
| Higher melphalan dose received | 64.4 | 59.7 | .520 |
| No. of systems with improvement at 1 y* | 1 (0, 1) | 0 (0, 1) | .021 |
| CR at 1, % | 39.4 | 41.6 | .772 |
Data represented as median (25th percentile, 75th percentile).